$56.24
1.683.08%
At Close: -
$56.20
-0.04-0.07%
After Hours: 6:59 PM EDT
15 minutes delayed
Comments
Loading...
CRISPR Therapeutics
CRSPNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
CRISPR Therapeutics (NASDAQ:CRSP) Stock, Analyst Ratings, Price Targets, Forecasts
CRISPR Therapeutics AG has a consensus price target of $77.19 based on the ratings of 29 analysts. The high is $160 issued by Truist Securities on December 11, 2023. The low is $30 issued by TD Cowen on December 11, 2023. The 3 most-recent analyst ratings were released by Needham, Piper Sandler, and Needham on June 27, 2024, June 17, 2024, and June 17, 2024, respectively. With an average price target of $93.67 between Needham, Piper Sandler, and Needham, there's an implied 66.67% upside for CRISPR Therapeutics AG from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Piper Sandler
Citigroup
Oppenheimer
JMP Securities
1calculated from analyst ratings
Analyst Ratings for CRISPR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay | — | Assumes | → Neutral | Get Alert |
| 06/27/2024 | Buy Now | 56.58% | Needham | Gil Blum | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 86.83% | Piper Sandler | Edward Tenthoff | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 56.58% | Needham | Gil Blum | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 49.47% | Citigroup | Yigal Nochomovitz | $89 → $84 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 69.04% | Oppenheimer | Jay Olson | $102 → $95 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 53.02% | JMP Securities | Silvan Tuerkcan | → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/09/2024 | Buy Now | 15.66% | Wells Fargo | Yanan Zhu | $70 → $65 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Reiterates | → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 19.22% | Barclays | Gena Wang | $80 → $67 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 56.58% | Needham | Gil Blum | $90 → $88 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | -7.47% | Baird | Jack Allen | $46 → $52 | Maintains | Neutral | Get Alert |
| 04/18/2024 | Buy Now | 58.36% | Citigroup | Yigal Nochomovitz | $88 → $89 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | 60.14% | Needham | Gil Blum | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 76.16% | Mizuho | Salim Syed | $82 → $99 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | -14.59% | Morgan Stanley | Terence Flynn | $46 → $48 | Maintains | Underweight | Get Alert |
| 02/22/2024 | Buy Now | 17.44% | RBC Capital | Luca Issi | $57 → $66 | Maintains | Sector Perform | Get Alert |
| 02/22/2024 | Buy Now | 24.56% | Wells Fargo | Jim Birchenough | $55 → $70 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 42.35% | Barclays | Gena Wang | $61 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 99.29% | Chardan Capital | Geulah Livshits | $110 → $112 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 60.14% | Needham | Gil Blum | $88 → $90 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 12/11/2023 | Buy Now | 1.42% | RBC Capital | Luca Issi | $50 → $57 | Maintains | Sector Perform | Get Alert |
| 12/11/2023 | Buy Now | 184.7% | Truist Securities | Joon Lee | $220 → $160 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 8.54% | Barclays | Gena Wang | $56 → $61 | Maintains | Equal-Weight | Get Alert |
| 12/11/2023 | Buy Now | -46.62% | TD Cowen | Tyler Van Buren | → $30 | Downgrade | Market Perform → Underperform | Get Alert |
| 12/11/2023 | Buy Now | 42.35% | JMP Securities | Silvan Tuerkcan | $74 → $80 | Maintains | Market Outperform | Get Alert |
| 12/11/2023 | Buy Now | 56.58% | Needham | Gil Blum | $85 → $88 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 291.46% | Truist Securities | Joon Lee | → $220 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | Buy Now | 45.91% | Mizuho | Salim Syed | → $82 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2023 | Buy Now | 31.67% | JMP Securities | Silvan Tuerkcan | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/13/2023 | Buy Now | -25.27% | Morgan Stanley | Terence Flynn | $43 → $42 | Maintains | Underweight | Get Alert |
| 11/07/2023 | Buy Now | -11.03% | RBC Capital | Luca Issi | $55 → $50 | Maintains | Sector Perform | Get Alert |
| 11/07/2023 | Buy Now | 51.25% | Needham | Gil Blum | $88 → $85 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 56.58% | Needham | Gil Blum | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | Buy Now | 56.58% | Needham | Gil Blum | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/27/2023 | Buy Now | 45.91% | Mizuho | Salim Syed | → $82 | Initiates | → Buy | Get Alert |
| 08/18/2023 | Buy Now | 24.56% | Citigroup | Yigal Nochomovitz | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/17/2023 | Buy Now | 24.56% | Citigroup | Yigal Nochomovitz | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/14/2023 | Buy Now | -23.49% | Morgan Stanley | Terence Flynn | $42 → $43 | Maintains | Underweight | Get Alert |
| 08/10/2023 | Buy Now | 81.49% | Oppenheimer | Jay Olson | → $102 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 12.1% | Credit Suisse | Richard Law | $62 → $63 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 33.45% | EF Hutton | Tony Butler | → $75 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 56.58% | Needham | Gil Blum | → $88 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 95.73% | Chardan Capital | Geulah Livshits | $123 → $110 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 31.67% | JMP Securities | Silvan Tuerkcan | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | 56.58% | Needham | Gil Blum | $82 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/09/2023 | Buy Now | 31.67% | JMP Securities | Silvan Tuerkcan | $70 → $74 | Maintains | Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | 33.45% | EF Hutton | Tony Butler | → $75 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | 13.88% | Barclays | Gena Wang | $61 → $64 | Maintains | Equal-Weight | Get Alert |
| 05/30/2023 | Buy Now | 33.45% | William Blair | Sami Corwin | → $75 | Reinstates | → Outperform | Get Alert |
| 05/23/2023 | Buy Now | 24.56% | Citigroup | Yigal Nochomovitz | $55 → $70 | Maintains | Neutral | Get Alert |
| 05/12/2023 | Buy Now | -25.27% | Morgan Stanley | Terence Flynn | $39 → $42 | Maintains | Underweight | Get Alert |
| 05/09/2023 | Buy Now | -11.03% | RBC Capital | Luca Issi | → $50 | Reiterates | → Sector Perform | Get Alert |
| 05/09/2023 | Buy Now | 24.56% | JMP Securities | Silvan Tuerkcan | → $70 | Reiterates | → Market Outperform | Get Alert |
| 05/09/2023 | Buy Now | 10.32% | Credit Suisse | Richard Law | $65 → $62 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | 13.88% | Stifel | Benjamin Burnett | $69 → $64 | Maintains | Hold | Get Alert |
| 05/09/2023 | Buy Now | 45.91% | Needham | Gil Blum | → $82 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 45.91% | Needham | Gil Blum | → $82 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 24.56% | JMP Securities | Silvan Tuerkcan | → $70 | Reiterates | → Market Outperform | Get Alert |
| 04/17/2023 | Buy Now | 33.45% | EF Hutton | Tony Butler | → $75 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 28.11% | Cantor Fitzgerald | Olivia Brayer | → $72 | Initiates | → Overweight | Get Alert |
| 04/03/2023 | Buy Now | 33.45% | EF Hutton | Tony Butler | → $75 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | -21.71% | Bernstein | William Pickering | → $44 | Initiates | → Market Perform | Get Alert |
| 03/18/2023 | Buy Now | -2.14% | Citigroup | Yigal Nochomovitz | $63 → $55 | Maintains | Neutral | Get Alert |
| 03/07/2023 | Buy Now | -18.15% | Baird | Jack Allen | → $46 | Initiates | → Neutral | Get Alert |
| 02/27/2023 | Buy Now | 24.56% | JMP Securities | Silvan Tuerkcan | → $70 | Reiterates | → Market Outperform | Get Alert |
| 02/27/2023 | Buy Now | -30.6% | Morgan Stanley | Terence Flynn | $37 → $39 | Maintains | Underweight | Get Alert |
| 02/23/2023 | Buy Now | 81.6% | Oppenheimer | Jay Olson | $110 → $102.06 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | 118.86% | Chardan Capital | Geulah Livshits | $153 → $123 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 15.66% | Credit Suisse | Richard Law | $78 → $65 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 33.45% | EF Hutton | Tony Butler | → $75 | Reiterates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | 45.91% | Needham | Gil Blum | $122 → $82 | Maintains | Buy | Get Alert |
| 01/19/2023 | Buy Now | 24.56% | JMP Securities | Silvan Tuerkcan | $100 → $70 | Maintains | Market Outperform | Get Alert |
| 01/05/2023 | Buy Now | 33.45% | EF Hutton | Tony Butler | → $75 | Initiates | → Buy | Get Alert |
| 11/23/2022 | Buy Now | 12.1% | Citigroup | Yigal Nochomovitz | $83 → $63 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | 35.23% | SVB Leerink | Mani Foroohar | $75 → $76 | Maintains | Outperform | Get Alert |
| 11/02/2022 | Buy Now | 24.56% | RBC Capital | Luca Issi | $79 → $70 | Maintains | Sector Perform | Get Alert |
| 11/02/2022 | Buy Now | 38.79% | Credit Suisse | Richard Law | $90 → $78 | Maintains | Neutral | Get Alert |
| 10/11/2022 | Buy Now | -34.16% | Morgan Stanley | Terence Flynn | → $37 | Initiates | → Underweight | Get Alert |
| 08/09/2022 | Buy Now | 60.14% | Credit Suisse | Richard Law | $74 → $90 | Maintains | Neutral | Get Alert |
| 08/09/2022 | Buy Now | 40.57% | RBC Capital | Luca Issi | $85 → $79 | Maintains | Sector Perform | Get Alert |
| 08/09/2022 | Buy Now | 174.02% | Chardan Capital | Geulah Livshits | $164 → $154 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 56.58% | Barclays | Gena Wang | $99 → $88 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/08/2022 | Buy Now | 90.39% | SVB Leerink | Rick Bienkowski | $112 → $107 | Maintains | Outperform | Get Alert |
| 08/02/2022 | Buy Now | 47.69% | Citigroup | Yigal Nochomovitz | $53 → $83 | Maintains | Neutral | Get Alert |
| 06/23/2022 | Buy Now | 117.08% | Oppenheimer | Jay Olson | $150 → $122 | Maintains | Outperform | Get Alert |
| 06/23/2022 | Buy Now | 6.76% | Evercore ISI Group | Liisa Bayko | $66 → $60 | Downgrade | Outperform → In-Line | Get Alert |
| 06/22/2022 | Buy Now | 191.81% | Chardan Capital | Geulah Livshits | $168 → $164 | Maintains | Buy | Get Alert |
| 06/22/2022 | Buy Now | -2.14% | Stifel | Benjamin Burnett | $57 → $55 | Maintains | Hold | Get Alert |
| 06/22/2022 | Buy Now | 115.3% | Piper Sandler | Edward Tenthoff | $115 → $121 | Maintains | Overweight | Get Alert |
| 06/17/2022 | Buy Now | 74.38% | BMO Capital | Kostas Biliouris | → $98 | Initiates | → Outperform | Get Alert |
| 06/13/2022 | Buy Now | 1.42% | Stifel | Benjamin Burnett | $52 → $57 | Maintains | Hold | Get Alert |
| 05/24/2022 | Buy Now | -18.15% | Goldman Sachs | Salveen Richter | $52 → $46 | Maintains | Neutral | Get Alert |
| 05/23/2022 | Buy Now | 104.63% | Piper Sandler | Edward Tenthoff | $180 → $115 | Maintains | Overweight | Get Alert |
| 05/17/2022 | Buy Now | -5.69% | Citigroup | Yigal Nochomovitz | $64 → $53 | Maintains | Neutral | Get Alert |
| 05/13/2022 | Buy Now | 117.08% | Needham | Gil Blum | $170 → $122 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | -7.47% | Goldman Sachs | Salveen Richter | $87 → $52 | Maintains | Neutral | Get Alert |
| 05/11/2022 | Buy Now | 166.9% | Oppenheimer | Jay Olson | $172 → $150 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for CRISPR Therapeutics (CRSP) stock?
The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Guggenheim on June 28, 2024. The analyst firm set a price target for $0.00 expecting CRSP to fall to within 12 months (a possible -100.00% downside). 47 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?
The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by Guggenheim, and CRISPR Therapeutics their neutral rating.
When was the last upgrade for CRISPR Therapeutics (CRSP)?
The last upgrade for CRISPR Therapeutics AG happened on August 18, 2023 when Citigroup raised their price target to $70. Citigroup previously had a neutral for CRISPR Therapeutics AG.
When was the last downgrade for CRISPR Therapeutics (CRSP)?
The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.
When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?
While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a with a price target of $0.00 to $0.00. The current price CRISPR Therapeutics (CRSP) is trading at is $56.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.